Information Provided By:
Fly News Breaks for September 11, 2015
BMY
Sep 11, 2015 | 09:13 EDT
Cowen significantly increased its 2017-2020 EPS estimates for Bristol-Myers, citing recent immune oncology data, increased estimates for Opdivo in lung cancer, what it sees as "impressive data" generated by the company's melanoma treatment, and the company's upcoming products. Cowen raised its 2017 EPs estimate for the company by 44% to $2.95, while increasing its 2018 EPS estimate by 24% to $3.65 its 2019 EPS estimate by 25% to $4.55, and its 2020 EPS estimate by 24% to $5.65. Cowen keeps an Outperform rating on the shares.